{"slideshow_credits": null, "snippet": "Opdivo didn\u2019t help my wife, or almost anyone else. So why can Bristol-Myers Squibb market it on TV?...", "abstract": "Op-Ed article by Matt Jablow of insurance company Evergreen Health calls for misleading television advertisements touting benefits of Pharmaceuticals to be pulled from air; cites Bristol-Myers Squibb ad for immunotherapy drug Opdivo for lung cancer patients, noting drug performed poorly in clinical trials.", "section_name": "Opinion", "print_page": "23", "document_type": "article", "byline": {"person": [{"firstname": "Matt", "role": "reported", "lastname": "JABLOW", "rank": 1, "organization": ""}], "original": "By MATT JABLOW"}, "web_url": "http://www.nytimes.com/2016/08/09/opinion/cancer-drug-ads-vs-cancer-drug-reality.html", "lead_paragraph": "Opdivo didn\u2019t help my wife, or almost anyone else. So why can Bristol-Myers Squibb market it on TV?", "headline": {"print_headline": "Drug Ads vs. Drug Reality", "main": "Cancer-Drug Ads vs. Cancer-Drug Reality", "content_kicker": "Op-Ed Contributor", "kicker": "Op-Ed Contributor"}, "_id": "57aa4d5a95d0e021d797f79c", "word_count": "776", "multimedia": [{"height": 126, "url": "images/2016/08/09/opinion/09JABLOW-web/09JABLOW-web-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2016/08/09/opinion/09JABLOW-web/09JABLOW-web-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 432, "url": "images/2016/08/09/opinion/09JABLOW-web/09JABLOW-web-articleLarge.jpg", "legacy": {"xlarge": "images/2016/08/09/opinion/09JABLOW-web/09JABLOW-web-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "432"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2016/08/09/opinion/09JABLOW-web/09JABLOW-web-thumbStandard-v2.jpg", "legacy": {"thumbnail": "images/2016/08/09/opinion/09JABLOW-web/09JABLOW-web-thumbStandard-v2.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2016-08-09T04:00:00+0000", "source": "The New York Times", "news_desk": "OpEd", "keywords": [{"name": "subject", "value": "Lung Cancer", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Clinical Trials", "is_major": "N", "rank": "2"}, {"name": "subject", "value": "Advertising and Marketing", "is_major": "Y", "rank": "3"}, {"name": "organizations", "value": "Bristol Myers Squibb Company", "is_major": "Y", "rank": "4"}, {"name": "organizations", "value": "Food and Drug Administration", "is_major": "N", "rank": "5"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "6"}], "blog": [], "subsection_name": null, "type_of_material": "Op-Ed"}